CVD Risk and Prevention in Early Glucose Intolerance.

Trial Profile

CVD Risk and Prevention in Early Glucose Intolerance.

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Aspirin; Olmesartan medoxomil; Thioctic acid
  • Indications Cardiovascular disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Jun 2012 Actual patient number changed from 4 to 84 as reported by
    • 21 Jun 2011 Actual end date (May 2011) and actual patient number (88) added, as reported by record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top